Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Retained Earnings (2016 - 2025)

Traws Pharma's Retained Earnings history spans 14 years, with the latest figure at $6000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $6000.0 for Q4 2025, up 114.29% from a year ago — trailing twelve months through Dec 2025 was $6000.0 (up 114.29% YoY), and the annual figure for FY2025 was $6000.0, up 114.29%.
  • Retained Earnings for Q4 2025 was $6000.0 at Traws Pharma, up from -$632.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $9000.0 in Q2 2025 to a low of -$632.5 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$51500.0 (2022), against an average of -$221.3 million.
  • The sharpest move saw Retained Earnings plummeted 22643350.0% in 2022, then soared 114.29% in 2025.
  • Year by year, Retained Earnings stood at -$444.7 million in 2021, then surged by 99.99% to -$33000.0 in 2022, then skyrocketed by 30.3% to -$23000.0 in 2023, then plummeted by 82.61% to -$42000.0 in 2024, then soared by 114.29% to $6000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $6000.0, -$632.5 million, and $9000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.